IL37 and myeloid sarcoma: The combined comparison of in silico analysis and in vivo data appear in conflict with regard to the finding that a significant reduction in IL37 expression was observed in PBMCs from MS patients undergoing exacerbation of the disease in the in silico analysis whereas augmented levels of IL37 were observed in the circulation of MS patients suffering an exacerbation.